Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations. [electronic resource]
Producer: 20200713Description: 1135-1150.e6 p. digitalISSN:- 1932-7420
- Acetates -- pharmacology
- Animals
- Carcinoma, Hepatocellular -- drug therapy
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Child
- Child, Preschool
- Disease Models, Animal
- Female
- Glutamate-Ammonia Ligase -- genetics
- Glutamine -- metabolism
- Hepatocytes -- metabolism
- Humans
- Infant
- Liver Neoplasms -- drug therapy
- Male
- Mechanistic Target of Rapamycin Complex 1 -- antagonists & inhibitors
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mutation
- Phenols -- pharmacology
- Retrospective Studies
- Sirolimus -- pharmacology
- TOR Serine-Threonine Kinases -- genetics
- Transfection
- Wnt Signaling Pathway -- genetics
- beta Catenin -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.